Show simple item record

dc.contributor.authorAletaha, Daniel
dc.contributor.authorNeogi, Tuhina
dc.contributor.authorSilman, Alan J.
dc.contributor.authorFunovits, Julia
dc.contributor.authorFelson, David T.
dc.contributor.authorBingham, Clifton O. III
dc.contributor.authorBirnbaum, Neal S.
dc.contributor.authorBurmester, Gerd R.
dc.contributor.authorBykerk, Vivian P.
dc.contributor.authorCohen, Marc D.
dc.contributor.authorCombe, Bernard
dc.contributor.authorCostenbader, Karen H.
dc.contributor.authorDougados, Maxime
dc.contributor.authorEmery, Paul
dc.contributor.authorFerraccioli, Gianfranco
dc.contributor.authorHazes, Johanna M. W.
dc.contributor.authorHobbs, Kathryn
dc.contributor.authorHuizinga, Tom W. J.
dc.contributor.authorKavanaugh, Arthur
dc.contributor.authorKay, Jonathan
dc.contributor.authorKvien, Tore K.
dc.contributor.authorLaing, Timothy
dc.contributor.authorMease, Philip
dc.contributor.authorMenard, Henri A.
dc.contributor.authorMoreland, Larry W.
dc.contributor.authorNaden, Raymond L.
dc.contributor.authorPincus, Theodore
dc.contributor.authorSmolen, Josef S.
dc.contributor.authorStanislawska-Biernat, Ewa
dc.contributor.authorSymmons, Deborah
dc.contributor.authorTak, Paul P.
dc.contributor.authorUpchurch, Katherine S.
dc.contributor.authorVencovsky, Jiri
dc.contributor.authorWolfe, Frederick
dc.contributor.authorHawker, Gillian
dc.date2022-08-11T08:10:51.000
dc.date.accessioned2022-08-23T17:22:32Z
dc.date.available2022-08-23T17:22:32Z
dc.date.issued2010-09-01
dc.date.submitted2015-04-17
dc.identifier.citationArthritis Rheum. 2010 Sep;62(9):2569-81. doi: 10.1002/art.27584. <a href="http://dx.doi.org/10.1002/art.27584">Link to article on publisher's site</a>
dc.identifier.issn0004-3591 (Linking)
dc.identifier.doi10.1002/art.27584
dc.identifier.pmid20872595
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48769
dc.description<p>This article was published simultaneously in the September 2010 issue of <em>Annals of the Rheumatic Diseases</em>. PubMed id: 20699241</p>
dc.description.abstractOBJECTIVE: The 1987 American College of Rheumatology (ACR; formerly, the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized for their lack of sensitivity in early disease. This work was undertaken to develop new classification criteria for RA. METHODS: A joint working group from the ACR and the European League Against Rheumatism developed, in 3 phases, a new approach to classifying RA. The work focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between those who were and those who were not at high risk for persistent and/or erosive disease--this being the appropriate current paradigm underlying the disease construct "rheumatoid arthritis." RESULTS: In the new criteria set, classification as "definite RA" is based on the confirmed presence of synovitis in at least 1 joint, absence of an alternative diagnosis that better explains the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in 4 domains: number and site of involved joints (score range 0-5), serologic abnormality (score range 0-3), elevated acute-phase response (score range 0-1), and symptom duration (2 levels; range 0-1). CONCLUSION: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features. This will refocus attention on the important need for earlier diagnosis and institution of effective disease-suppressing therapy to prevent or minimize the occurrence of the undesirable sequelae that currently comprise the paradigm underlying the disease construct "rheumatoid arthritis."
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=20872595&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1002/art.27584
dc.subjectAcute-Phase Reaction
dc.subjectAlgorithms
dc.subjectArthritis, Rheumatoid
dc.subjectEarly Diagnosis
dc.subjectEurope
dc.subjectHumans
dc.subjectInternational Cooperation
dc.subjectNorth America
dc.subjectSeverity of Illness Index
dc.subjectSocieties, Medical
dc.subjectSynovitis
dc.subjectTerminology as Topic
dc.subjectTime Factors
dc.subjectMusculoskeletal Diseases
dc.subjectRheumatology
dc.subjectSkin and Connective Tissue Diseases
dc.title2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
dc.typeJournal Article
dc.source.journaltitleArthritis and rheumatism
dc.source.volume62
dc.source.issue9
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/rheumatology_pubs/95
dc.identifier.contextkey7002919
html.description.abstract<p>OBJECTIVE: The 1987 American College of Rheumatology (ACR; formerly, the American Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized for their lack of sensitivity in early disease. This work was undertaken to develop new classification criteria for RA.</p> <p>METHODS: A joint working group from the ACR and the European League Against Rheumatism developed, in 3 phases, a new approach to classifying RA. The work focused on identifying, among patients newly presenting with undifferentiated inflammatory synovitis, factors that best discriminated between those who were and those who were not at high risk for persistent and/or erosive disease--this being the appropriate current paradigm underlying the disease construct "rheumatoid arthritis."</p> <p>RESULTS: In the new criteria set, classification as "definite RA" is based on the confirmed presence of synovitis in at least 1 joint, absence of an alternative diagnosis that better explains the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in 4 domains: number and site of involved joints (score range 0-5), serologic abnormality (score range 0-3), elevated acute-phase response (score range 0-1), and symptom duration (2 levels; range 0-1).</p> <p>CONCLUSION: This new classification system redefines the current paradigm of RA by focusing on features at earlier stages of disease that are associated with persistent and/or erosive disease, rather than defining the disease by its late-stage features. This will refocus attention on the important need for earlier diagnosis and institution of effective disease-suppressing therapy to prevent or minimize the occurrence of the undesirable sequelae that currently comprise the paradigm underlying the disease construct "rheumatoid arthritis."</p>
dc.identifier.submissionpathrheumatology_pubs/95
dc.contributor.departmentDepartment of Medicine, Division of Rheumatology
dc.source.pages2569-81


This item appears in the following Collection(s)

Show simple item record